New nationwide Alzheimer’s study coordinated by UCSD
SAN DIEGO (KUSI) – A new nationwide Alzheimer’s clinical study is being coordinated by UC San Diego. The study is seeking to slow or stop memory loss in people diagnosed with mild to moderate Alzheimer’s disease through testing of a prodrug called troriluzole.
The trial lasts almost a year and is very simple, involving a pill a day and visits to the clinic. Participants ages 50-85 are needed at the UC San Diego site.
Troriluzole: Is a drug that modulates glutamate. It’s a prodrug of riluzole, a drug first approved by the FDA in 1995 to slightly slow disease progression in patients with ALS. Prodrugs are inactive medications that transform into the drug within the body. When a person takes troriluzole, the body converts it into the active drug riluzole. This means the prodrug troriluzole can be taken once a day, while riluzole is administered twice a day. Unlike riluzole, patients don’t need to fast before and after taking troriluzole, and troriluzole has potential for better safety and tolerability than riluzole.
Here is a link to the T2 Protect AD website, which includes the list of T2 sites/cities: http://www.t2protect.org/